Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer

To evaluate the safety and efficacy of cabozantinib combined with docetaxel.

[1]  T. Choueiri,et al.  Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study. , 2020 .

[2]  F. Jamali,et al.  Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma , 2020, BMC Cancer.

[3]  J. Carles,et al.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[4]  M. Loda,et al.  The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance , 2019, Clinical Cancer Research.

[5]  E. Basch,et al.  Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. , 2019, European urology.

[6]  S. Gregory,et al.  Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Meltzer,et al.  Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations , 2018, Journal of Immunotherapy for Cancer.

[8]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[9]  W. Lu,et al.  Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[10]  F. Saad,et al.  Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Grüllich.  Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. , 2018, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[12]  F. Saad,et al.  Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Yihai Cao,et al.  Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy , 2017, Proceedings of the National Academy of Sciences.

[14]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[15]  David C. Smith,et al.  Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. , 2017, European journal of cancer.

[16]  F. Saad,et al.  Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Steinberg,et al.  Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer , 2016, BJU international.

[18]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[19]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[20]  J. Burke,et al.  Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. , 2015, The Lancet. Oncology.

[21]  E. Antonarakis,et al.  Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  David C. Smith,et al.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[24]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[25]  P. Kantoff,et al.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Steinberg,et al.  Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[28]  J. Verweij,et al.  Clinical Pharmacokinetics of Docetaxel , 2006, Clinical pharmacokinetics.

[29]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[30]  M. Aapro,et al.  Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation , 2004, Cancer Chemotherapy and Pharmacology.

[31]  Henry F. Diaz,et al.  ENSO variability, teleconnections and climate changeThis article is a US Government work and is in the public domain in the USA. , 2001 .

[32]  S. Steinberg,et al.  Clinical trial designs for the early clinical development of therapeutic cancer vaccines. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Rivory,et al.  Clinical Pharmacokinetics of Docetaxel , 1999, Clinical pharmacokinetics.

[34]  R. Bruno,et al.  Pharmacokinetics and metabolism of Taxotere (docetaxel). , 1993, Cancer surveys.